共 143 条
[1]
Nassif ME(2019)Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction Circulation. 19 100-116
[2]
Windsor S(2021)Heart failure with mid-range or mildly reduced ejection fraction Nat Rev Cardiol 70 2476-2486
[3]
Tang F(2019)Positive airway pressure therapy for the treatment of central sleep apnoea associated with heart failure Cochrane database Syst Rev 19 1574-1585
[4]
Khariton Y(2017)Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes J Am Coll Cardiol 3 67-92
[5]
Husain M(2017)Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC heart failure long-term registry Eur J Heart Fail 324 488-504
[6]
Inzucchi S(2010)Heart failure: management of patients with left-ventricular systolic dysfunction: quick reference guide for clinicians J Pharma Care Pain Sym Control 75 23-32
[7]
Savarese G(2020)Heart failure with reduced ejection fraction: a review JAMA J Am Med Assoc 22 1937-1938
[8]
Stolfo D(2020)Medical therapies for heart failure with preserved ejection fraction Hypertens 138 116-8
[9]
Sinagra G(2020)November 2020 at a glance: focus on comorbidities and medical treatment Eur J Heart Fail 381 1999-2008
[10]
Lund LH(2021)Meta-analysis of dedicated renal outcome trials assessing the cardio-renal efficacy of sodium-glucose Co-transporter-2 inhibitors in patients with chronic kidney disease and albuminuria Am J Cardiol 100 e26431-105